Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer
- PMID: 33064985
- DOI: 10.1016/j.cell.2020.09.052
Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer
Abstract
PD1/PD-L1-directed immunotherapy, alone or in combination with chemotherapy, dominates the initial treatment of metastatic non-small cell lung cancer. However, our ability to predict who will benefit from these approaches is limited. In this issue of Cell, Nabet et al. report a novel, blood-based methodology to more accurately predict durable disease control with immunotherapy.
Copyright © 2020 Elsevier Inc. All rights reserved.
Comment on
-
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.Cell. 2020 Oct 15;183(2):363-376.e13. doi: 10.1016/j.cell.2020.09.001. Epub 2020 Oct 1. Cell. 2020. PMID: 33007267 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials